Related Experiment Video
Updated: Jun 16, 2026
07:17
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
Published on: May 9, 2018
Sexual and Urinary Outcomes After iTind for Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis
Fernando Loyola-Nieto1, Giulia Almiron da R Soares2, Marcelo Mass Lindenbaum3
1Men's Health Section, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH; Universidad Panamericana School of Medicine, Mexico City, Mexico.
Urology
|June 13, 2026
Summary
The iTind device offers significant improvements in urinary symptoms for men with benign prostatic hyperplasia (BPH) over 12 months. Sexual function, including ejaculation and erectile function, remained largely unchanged, with low reintervention rates.
Area of Science:
- Urology
- Medical Devices
- Men's Health
Background:
- Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) significantly impact men's quality of life.
- Current treatments for BPH carry risks of sexual dysfunction, necessitating alternative therapeutic options.
Purpose of the Study:
- To evaluate the efficacy and safety of the temporary implantable nitinol device (iTind) for LUTS/BPH.
- To characterize urinary and sexual outcomes following iTind therapy through a systematic review and meta-analysis.
Main Methods:
- A systematic review and single-arm meta-analysis of prospective studies.
- Searched PubMed, Embase, and Cochrane Central for studies on iTind treatment for LUTS/BPH.
- Assessed changes in International Prostate Symptom Score (IPSS), IPSS quality-of-life (IPSS-QoL), maximum urinary flow rate (Qmax), post-void residual volume (PVR), and Sexual Health Inventory for Men (SHIM/IIEF-5) scores.
Main Results:
- Five prospective studies (431 patients) were included, with 12-month follow-up.
- Significant improvements observed in IPSS (-10.44 points) and IPSS-QoL (-2.08 points).
- Qmax increased (+5.38 mL/s), PVR decreased (-12.21 mL), and sexual function (SHIM/IIEF-5) showed no significant change. Ejaculatory function was preserved, with no de novo retrograde ejaculation. 12-month reintervention rates were low (0-4.7%).
Conclusions:
- iTind therapy provides consistent and clinically meaningful improvements in urinary outcomes up to 12 months.
- The device preserves ejaculatory function and does not significantly alter erectile function.
- Further comparative trials using validated sexual function instruments are recommended.
Related Concept Videos
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
01:30Urinary Tract Calculi III: Medical Management
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
01:19Urodynamic Studies: Uroflowmetry
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
01:25Urinary Tract Calculi VI: Surgical Management
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...